Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 12,609 · FY2024 18,890 — 3-yr total 31,499
Pharmaceutical importer/distributor active in the Georgian market.
| Line item | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| 4,509 | 26,097 | 29,667 | 50,145 | +123.2% | |
| Total Non-Current Assets | 229 | 909 | 2,109 | 2,678 | +126.9% |
| TOTAL ASSETS | 4,738 | 27,006 | 31,776 | 52,823 | +123.4% |
| 4,813 | 18,285 | 13,379 | 20,066 | +61.0% | |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | |
| TOTAL LIABILITIES | 4,813 | 18,285 | 13,379 | 20,066 | +61.0% |
| 74 | 8,720 | 18,396 | 32,757 | nmf | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||
| Total Debt | 403 | 419 | 420 | 424 | +1.7% |
| Cash & Equivalents | 45 | 713 | 99 | 29 | -13.2% |
| Net Debt | 358 | 294 | 321 | 394 | +3.3% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →